"The Marie Yeager Cancer Center makes it possible for patients and their families to go to just one facility for the majority of their cancer care needs. The center includes a highly qualified team of cancer specialists and state-of-the-art technology for cancer detection and treatment, all in an environment designed to promote health and healing. Other benefits include an environment designed to reduce stress and anxiety and promote hope and healing, dedicated pharmacist mixing chemotherapy on-site, enhanced collaboration among regional organizations that share the goal of cancer awareness, prevention, and education, and improved accessibility and convenience to necessary programs and services, including clinical trials."

During the past decade, Marie Yeager Cancer Center conducted 142 clinical trials. In the 10-year time frame, 142 clinical trials started and 102 clinical trials were completed, i.e. on average, 71.8% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 61 clinical trials were completed. i.e. 96.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Marie Yeager Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 113 trials, followed by "SWOG Cancer Research Network" with 37 trials sponsored, "Alliance for Clinical Trials in Oncology" with 32 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 18 trials sponsored and "Gynecologic Oncology Group" with 18 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Marie Yeager Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 123 trials as a collaborator, "NRG Oncology" with 21 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator and "NCIC Clinical Trials Group" with 5 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Marie Yeager Cancer Center" are "Recurrent Breast Carcinoma" (10 trials), "Invasive Breast Carcinoma" (9 trials), "Recurrent Ovarian Carcinoma" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials) and "Stage IV Breast Cancer AJCC v6 and v7" (9 trials). Many other conditions were trialed in "Marie Yeager Cancer Center" in a lesser frequency.

Most popular intervention types in "Marie Yeager Cancer Center" are "Drug" (190 trials), "Other" (163 trials), "Biological" (96 trials), "Procedure" (57 trials) and "Radiation" (31 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (86 trials), "Quality-of-Life Assessment" (68 trials), "Questionnaire Administration" (48 trials), "Paclitaxel" (33 trials) and "Carboplatin" (32 trials). Other intervention names were less common.

The vast majority of trials in "Marie Yeager Cancer Center" are 182 trials for "All" genders, 48 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Marie Yeager Cancer Center". undefined are not yet recruiting, 60 are recruiting, 105 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 51 completed trials in Marie Yeager Cancer Center, 7 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Marie Yeager Cancer Center, 6 "Phase 1" clinical trials were conducted, 113 "Phase 2" clinical trials and 118 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".